Last reviewed · How we verify
Reference GIR
At a glance
| Generic name | Reference GIR |
|---|---|
| Also known as | Metformin |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhea
- Anemia
- Abdominal distension
- Abdominal pain
- Frequent bowel movements
Key clinical trials
- Effect of Referent Type on Balance in Action Observation. (NA)
- Glucophage Immediate Release (GIR) China Bioequivalence Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reference GIR CI brief — competitive landscape report
- Reference GIR updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI